Indatuximab ravtansine

N/A

Report date: 2024/02/05 13:54:47

Base Information

Drug NameIndatuximab ravtansine
Drug Alias NameBT-062nBT-062
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-CD138Wnt signalling pathway inhibitors
TargetsSyndecan-1Tubulin
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiotest Pharma Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiotest AgBiotest Pharmaceuticals Co
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksWikipedia